How to Diagnose Cancer Better Using Multiple Blood Markers and Patient Data
This patent describes a method for improving cancer diagnosis by combining measurements of several biological markers with patient-specific information like age or body mass, transforming them into a special score, and then comparing that score to a model of known cancer cases.
Original patent title: “Method for improving disease diagnosis using measured analytes”
This patent describes a method for improving cancer diagnosis by combining measurements of several biological markers with patient-specific information like age or body mass, transforming them into a special score, and then comparing that score to a model of known cancer cases. Owned by OTRACES with 22 claims, and it is expected to expire in 2043.
Coverage
What does this patent actually cover?
This method aims to improve cancer diagnosis and treatment by analyzing a subject's biological samples. First, it receives concentrations of at least three specific biological markers, called analytes, from a patient's sample (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1a). Then, it selects additional patient details, known as meta-variables, such as age, body mass, or menopausal status, which are known to vary in the general population (Claim 1b, Claim 2). These analyte concentrations are then transformed, using both population data and the selected meta-variables, into a special unitless number called a "pseudo-concentration" for each analyte (Claim 1c). These pseudo-concentrations are scored against a pre-built model of pseudo-concentrations from people known to have or not have the disease (Claim 1d). Finally, based on this score, the method diagnoses whether the subject has cancer, provided the diagnostic model performs with at least 75% accuracy in avoiding false positives and negatives, and then suggests administering anti-cancer drugs (Claim 1e). For example, a doctor could use this system to get a more accurate cancer diagnosis for a patient by inputting their blood test results and their age, and the system would output a diagnosis and treatment recommendation.
The gap
What does this patent NOT cover?
- Does not cover diagnostic methods that use fewer than three predetermined analytes.
- Does not cover diagnostic methods that do not incorporate meta-variables specific to the subject's population, like age or body mass.
- Does not cover diagnostic methods where the raw analyte concentrations are not transformed into unitless, clinically predictive pseudo-concentrations.
- Does not cover diagnostic models with a false negative and false positive performance worse than 75%.
- Does not cover diagnostic methods that only provide a diagnosis without also including the administration of anti-cancer drugs.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The truly clever part is transforming raw analyte concentrations into "pseudo-concentrations" by factoring in patient-specific meta-variables and population distribution characteristics. This normalizes the data, making the diagnostic score more robust and less prone to variations caused by individual differences, thus improving diagnostic accuracy.
The Patent Drawing

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Personalized cancer diagnostic panels
AI-powered medical diagnostic systems
Advanced blood tests for early disease detection
Precision oncology treatment planning tools
Why it matters
The bigger picture
Accurate and early cancer diagnosis is critical for effective treatment. This patent matters because it proposes a way to make diagnostic tests more precise by accounting for individual patient characteristics and population differences, rather than relying solely on raw biomarker levels. By integrating meta-variables, it aims to reduce misdiagnoses, which can lead to better patient outcomes and more targeted treatment plans. This approach could help personalize medicine by making diagnostic results more relevant to each unique patient.
Filed
May 5, 2023
Market context
Who's building on this
Companies in this space
OTRACES, the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, is likely developing or licensing technologies based on this method. Companies like Foundation Medicine, Guardant Health, and Tempus AI are actively working in the space of precision oncology, leveraging advanced diagnostics and AI to personalize cancer treatment. These companies focus on analyzing complex biological data and patient characteristics to improve diagnostic accuracy and guide therapeutic decisions.
Market impact
This patent could contribute to a market shift towards more personalized and accurate cancer diagnostics. By integrating patient-specific data, it aims to reduce diagnostic errors, potentially leading to earlier and more effective interventions. This approach could influence how new diagnostic tests are developed and validated, pushing the industry towards more sophisticated, data-driven models that go beyond simple biomarker thresholds. It also reinforces the trend of combining diagnostics with treatment recommendations.
Claim 1 — Plain English
What this patent covers
This method aims to improve cancer diagnosis and treatment by analyzing a subject's biological samples. First, it receives concentrations of at least three specific biological markers, called analytes, from a patient's sample (Claim 1a). Then, it selects additional patient details, known as meta-variables, such as age, body mass, or menopausal status, which are known to vary in the general population (Claim 1b, Claim 2). These analyte concentrations are then transformed, using both population data and the selected meta-variables, into a special unitless number called a "pseudo-concentration" for each analyte (Claim 1c). These pseudo-concentrations are scored against a pre-built model of pseudo-concentrations from people known to have or not have the disease (Claim 1d). Finally, based on this score, the method diagnoses whether the subject has cancer, provided the diagnostic model performs with at least 75% accuracy in avoiding false positives and negatives, and then suggests administering anti-cancer drugs (Claim 1e). For example, a doctor could use this system to get a more accurate cancer diagnosis for a patient by inputting their blood test results and their age, and the system would output a diagnosis and treatment recommendation.
The clever bit
The truly clever part is transforming raw analyte concentrations into "pseudo-concentrations" by factoring in patient-specific meta-variables and population distribution characteristics. This normalizes the data, making the diagnostic score more robust and less prone to variations caused by individual differences, thus improving diagnostic accuracy.
What it does not cover
- Does not cover diagnostic methods that use fewer than three predetermined analytes.
- Does not cover diagnostic methods that do not incorporate meta-variables specific to the subject's population, like age or body mass.
- Does not cover diagnostic methods where the raw analyte concentrations are not transformed into unitless, clinically predictive pseudo-concentrations.
- Does not cover diagnostic models with a false negative and false positive performance worse than 75%.
- Does not cover diagnostic methods that only provide a diagnosis without also including the administration of anti-cancer drugs.
Patent timeline
Application submitted to the patent office
Patent enters public domain
PatentBrief Score
Impact Score
Limited data
Citation count
0/40
No citations yet
Claim breadth
15/20
Broad claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
0/20
Older than 20 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$39K – $125K
Midpoint $78K · 16.4 yr remaining · industry ×2.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
The original legal language
Original claims
22 claims as filed with the patent office.
Concepts involved
Citations
Patent lineage
Cite this patent
LINGENFELTER, K., Marefat, M., & KRASIK, G. How to Diagnose Cancer Better Using Multiple Blood Markers and Patient Data (U.S. Patent No. 20,230,274,838). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/20230274838/method-for-improving-disease-diagnosis-using-measured-analytes
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US20230274838"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 8053198 · 2011 · Meso Scale Technologies
Method for Diagnosing Ovarian Cancer Using Biomarkers
US 20240117444 · Mammogen
Using Blood and Saliva mRNA to Detect Breast Cancer
US 12735751 · 2026
Finding Rare Genetic Changes in Blood Using DNA Fragments
US 12737884 · 2026
AI Predicts Prostate Cancer Spread from Medical Scans
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does How to Diagnose Cancer Better Using Multiple Blood Markers and Patient Data cover?
This patent describes a method for improving cancer diagnosis by combining measurements of several biological markers with patient-specific information like age or body mass, transforming them into a special score, and then comparing that score to a model of known cancer cases.
Who owns patent US 20230274838?
This patent is owned by OTRACES.
When does this patent expire?
This patent is expected to expire on May 5, 2043, when the invention enters the public domain.
What problem does this patent solve?
Accurate and early cancer diagnosis is critical for effective treatment. This patent matters because it proposes a way to make diagnostic tests more precise by accounting for individual patient characteristics and population differences, rather than relying solely on raw biomarker levels. By integrating meta-variables, it aims to reduce misdiagnoses, which can lead to better patient outcomes and more targeted treatment plans. This approach could help personalize medicine by making diagnostic results more relevant to each unique patient.
What does this patent NOT cover?
Does not cover diagnostic methods that use fewer than three predetermined analytes.
Patent monitoring



